CryoPort, Inc. (CYRX) - 10-K Summary for Fiscal Year Ended March 31, 2009
Business Context and Reporting Period
Company: CryoPort, Inc.
Reporting Period: Fiscal year ended March 31, 2009
Business Model: CryoPort develops and manufactures frozen shipping containers for the global movement of biological specimens (e.g., pharmaceuticals, vaccines, infectious substances) at cryogenic temperatures (below -150°C). The company is transitioning from selling reusable shippers to a service-based model utilizing the "CryoPort Express" system, which provides a turnkey shipping solution including web-based order entry and reusable/disposable shippers.
Operations: The company operates from a leased 12,000 sq. ft. facility in Lake Forest, California, with approximately 12 employees and consultants.
Key Financial Metrics
| Metric | Fiscal 2009 | Fiscal 2008 |
|---|---|---|
| Net Sales | $35,124 | $83,564 |
| Gross Loss | ($511,028) | ($302,807) |
| Operating Expenses (SG&A + R&D) | $2,684,665 | $2,717,005 |
| Interest Expense | $2,693,383 | $1,592,718 |
| Loss on Extinguishment of Debt | $10,846,573 | $0 |
| Net Loss | ($16,705,151) | ($4,564,054) |
| Net Loss Per Share | ($0.41) | ($0.12) |
| Cash Used in Operating Activities | ($2,586,470) | Not explicitly stated in text |
| Total Assets (March 31, 2009) | $1,572,556 | $3,460,889 |
| Total Liabilities (March 31, 2009) | $6,348,460 (Debt) | $3,461,070 (Debt) |
| Working Capital Deficit | ($3,693,015) | Not explicitly stated |
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 58% to $35,124 due to the discontinuation of the reusable shipper product line in early fiscal 2009 to focus resources on the CryoPort Express system.
- Significant Non-Cash Loss: The net loss increased 266% primarily due to a $10.8 million non-cash loss on the extinguishment of debt. This resulted from amendments to the October 2007 and May 2008 convertible debentures, which altered the net present value of the debt and related warrants.
- Debt Restructuring: Total indebtedness increased to approximately $6.35 million. The company amended its debentures in January 2009, extending payment terms and adjusting conversion prices, which triggered the debt extinguishment accounting treatment.
- Cost of Sales: Increased 41% to $546,152 despite lower sales, driven by fixed overhead costs and plant underutilization during the product transition.
Guidance, Outlook, Risks, and Contingencies
Going Concern: The company's independent auditors have raised substantial doubt about its ability to continue as a going concern due to recurring losses, negative cash flows, and a working capital deficit. Management acknowledges the need for additional capital to commercialize the CryoPort Express system.
Outlook & Strategy:
- Commercialization: The company is in the pilot phase of the CryoPort Express system, having secured limited introductory sales. Full commercialization is expected in the next fiscal year.
- Capital Needs: Management is aggressively seeking approximately $10 million in long-term funding. As of June 22, 2009, the company had raised approximately $906,630 in a private placement of convertible debentures (targeting $1.5 million).
- Cost Containment: The company is minimizing cash burn by utilizing stock-based compensation, deferring salaries, and relying on part-time consultants.
Risks:
- Liquidity: Current liabilities exceed current assets by $3.7 million. The company relies on debt financing and equity raises to fund operations.
- Debt Covenants: The company has missed payments on related-party notes but is within a 120-day grace period. Failure to secure funding could lead to default on senior secured debentures.
- Market Penetration: Success depends on the ability to secure strategic partnerships with freight carriers and large pharmaceutical customers, which are not yet guaranteed.
Key Facts for Investor Verification
- Debt Extinguishment Impact: Verify the $10.8 million loss on debt extinguishment is a non-cash accounting adjustment resulting from debt amendments, not an operational cash outflow.
- Liquidity Runway: Confirm the status of the $1.5 million private placement offering and whether the company has secured the additional $10 million required for full commercialization.
- Related Party Transactions: Review the $1.13 million in outstanding notes to related parties (former directors) and the status of deferred payments.
- Revenue Transition: Assess the progress of the CryoPort Express system pilot sales and the timeline for generating significant recurring revenue to replace the discontinued reusable shipper sales.
- Stock Dilution: Note the high number of outstanding options and warrants (approx. 37.2 million shares) and the low conversion prices ($0.51) on recent debentures, which pose significant dilution risk upon conversion.